Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 sept. 2024 07h00 HE | Source: Biosplice Therapeutics, Inc.

Biosplice Therapeutics Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)

Biosplice Announces Initiation of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Trial Sponsored by the National Cancer Institute (NCI)
05 avr. 2011 13h00 HE | Source: Semafore Pharmaceuticals

Semafore Pharmaceuticals Reports New Preclinical Data for Multi-Kinase, PI3K/mTOR Inhibitor SF1126 at AACR

INDIANAPOLIS, April 5, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals today announced encouraging preclinical results for its lead product candidate, SF1126, in certain B-cell malignancies. The...
09 mars 2011 07h30 HE | Source: Semafore Pharmaceuticals

Semafore Pharmaceuticals Announces Presentation Highlighting Activity of Multi-Kinase, PI3K/mTOR Inhibitor SF1126 at 2011 AACR Annual Meeting

INDIANAPOLIS, March 9, 2011 (GLOBE NEWSWIRE) -- Semafore Pharmaceuticals announced today that preclinical data in B-cell malignancies for the company's lead product candidate SF1126 will be presented...